- Home
- ABIO
ABIO
ARCA biopharma Inc.
as 07-26-2024 4:00pm EST
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WESTMINSTER |
| Market Cap: | 47.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 120.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.56 - $4.49 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ARCA biopharma Inc. (ABIO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.45 | 94,537 | $326,303.91 | 1,891,312 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.46 | 21,963 | $76,062.26 | 1,796,775 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.46 | 33,500 | $116,067.45 | 1,774,812 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.43 | 16,917 | $58,091.29 | 1,741,312 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.54 | 17,600 | $62,216.00 | 1,724,395 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.41 | 29,892 | $101,973.57 | 1,706,795 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.41 | 5,000 | $17,050.00 | 1,676,903 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.43 | 23,326 | $80,015.18 | 1,671,903 | SEC Form 4 |
| JANUS HENDERSON GROUP PLC | ABIO | 10% Owner | Jul 2 '24 | Buy | $3.55 | 166,042 | $589,565.33 | 1,648,577 | SEC Form 4 |
Latest ARCA biopharma Inc. News
ABIO Breaking Stock News: Dive into ABIO Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)?
GlobeNewswire
3 months ago
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
Benzinga
4 months ago
Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details
GlobeNewswire
4 months ago
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
GlobeNewswire
6 months ago
ARCA biopharma Announces 2023 Financial Results
GuruFocus.com
6 months ago
Sierra Bancorp (BSRR) Reports Year-End Earnings, Emphasizes Strategic Growth Amidst Challenges
Business Wire
6 months ago
United Natural Foods Expands Supply Chain Evolution with Implementation of A.I.-Powered Warehouse Automation System in its New Manchester Distribution Center
GlobeNewswire
6 months ago
LED Lighting, EV Charging and Maintenance Solutions Provider Orion Hosts Q3 Call Wed., February 7th at 10am ET
Compare ABIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABIO ARCA biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.